SCHEMBL4350754

SCHEMBL4350754

CCS(=O)(=O)N(c1ncc(C(=O)c2ccccc2F)c(N)n1)C1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 15/20 0.48
CDK4 P11802 14/20 0.48
CCND1 P24385 14/20 0.48
CDK2 P24941 14/20 0.48
CCNB2 O95067 1/20 0.38
CCNE2 O96020 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNE1 P24864 1/20 0.38
CCND2 P30279 1/20 0.38
CCND3 P30281 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
PTPN11 Q06124 1/20 0.37
PAK1 Q13153 1/20 0.36
SLC6A4 P31645 3/20 0.35
SLC6A2 P23975 2/20 0.35
KCNH2 Q12809 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350208 0.90 CDK1 (0.47) CDK1CDK4CCND1CDK2PAK1
SCHEMBL3837688 0.87 CDK2 (0.42) CDK1CDK4CCND1CDK2CCNB2
SCHEMBL4348154 0.87 CDK1 (0.62) CDK1CDK4CCND1CDK2PAK1
SCHEMBL5738185 0.83 CDK1 (0.60) CDK1CDK4CCND1CDK2PAK1
SCHEMBL4363543 0.82 CDK1 (0.54) CDK1CDK4CCND1CDK2SLC6A4
SCHEMBL3522557 0.81 CDK2 (0.54) CDK1CDK4CCND1CDK2CCNB1
SCHEMBL4350406 0.79 CDK1 (0.52) CDK1CDK4CCND1CDK2SLC6A4
SCHEMBL5738072 0.79 CDK1 (0.52) CDK1CDK4CCND1CDK2SLC6A4
SCHEMBL4349331 0.79 CDK1 (0.52) CDK1CDK4CCND1CDK2SLC6A4
SCHEMBL5739352 0.79 CDK1 (0.52) CDK1CDK4CCND1CDK2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.